Lincoln Pharmaceuticals (NSE:LINCOLN) Accounts Payable: ₹849 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:LINCOLN Lincoln Pharmaceuticals Ltd NSE:LINCOLN
82 GF Score
Price ₹577.15
GF Value ₹720.32
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lincoln Pharmaceuticals Accounts Payable?

Lincoln Pharmaceuticals NSE:LINCOLN +0.87% 82 Accounts Payable is ₹849 Mil as of Mar. 2026. GuruFocus rates NSE:LINCOLN with a GF Score™ of 82/100 and a GF Value™ of ₹720.32 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Lincoln Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was ₹849 Mil.

Lincoln Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 (₹885 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹849 Mil).

Lincoln Pharmaceuticals's annual Accounts Payable increased from Mar. 2024 (₹724 Mil) to Mar. 2025 (₹849 Mil) but then declined from Mar. 2025 (₹849 Mil) to Mar. 2026 (₹849 Mil).

Lincoln Pharmaceuticals Accounts Payable Related Terms

Lincoln Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Lincoln Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lincoln Pharmaceuticals Accounts Payable Chart

Lincoln Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 716.67 508.67 724.40 849.48 848.63

Lincoln Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 849.48 0.00 884.80 0.00 848.63
NSE:LINCOLN
82GF Score
Lincoln Pharmaceuticals Ltd NSE:LINCOLN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lincoln Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹849 Mil mean?
Lincoln Pharmaceuticals (NSE:LINCOLN) has a Accounts Payable of ₹849 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lincoln Pharmaceuticals and its competitors.
Is Lincoln Pharmaceuticals' Accounts Payable too high?
Lincoln Pharmaceuticals' current Accounts Payable is ₹849 Mil. Overall, Lincoln Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' Accounts Payable compare to ZTS?
Lincoln Pharmaceuticals' Accounts Payable of ₹849 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lincoln Pharmaceuticals and its competitors. Lincoln Pharmaceuticals's current Accounts Payable is ₹849 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹720.32, compared to a current price of ₹577.15 — trading 19.9% below its estimated fair value. The current Accounts Payable is ₹849 Mil. Lincoln Pharmaceuticals' overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current Accounts Payable is ₹849 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued. The current stock price of ₹577.15 is trading 19.9% below its estimated GF Value™ of ₹720.32. GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:LINCOLN:

  • Accounts Payable: ₹849 Mil
  • GF Value™: ₹720.32 vs. price of ₹577.15 (19.9% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lincoln Pharmaceuticals Business Description

Other Exchanges 531633:India
Address Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
82GF Score

Get the complete analysis for NSE:LINCOLN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹577.15
Price
₹720.32
GF Value